

Evonik to showcase innovative cardiovascular and cognitive health ingredients at Vitafoods Europe

Evonik, a global partner to nutraceutical companies seeking to enhance the effectiveness of dietary supplements and functional food products, will showcase its range of cardiovascular and cognitive health ingredients at Vitafoods Europe in Geneva, Switzerland from May 15th to 17th at booth H20.

Thomas Hermann, Vice President Pharma and Food Ingredients for the Evonik Health Care Business Line, said: "Nutraceutical companies worldwide leverage our advanced health ingredients to create high-performance dietary supplements and functional foods. At Vitafoods, we look forward to discussing how Evonik can give companies a competitive advantage with products that target cardiovascular and cognitive health."

Evonik has a growing portfolio of advanced food ingredients with proven benefits that target specific health areas. Combined with a range of nutraceutical coatings and a global team with strong formulation development expertise, Evonik supports customers in the creation of dietary supplements and functional foods that boost effectiveness and are preferred by consumers.

Evonik's latest health ingredient is AvailOm®, a concentrated solid Omega-3 Lysine Complex. As the highest-load Omega-3 powder in its class, AvailOm® can be compressed into easy-to-swallow tablets that contain the equivalent dosage of two large fish-oil capsules. It also provides superior stability against oxidation, is easy to handle, and can be customized to meet specific formulation requirements.

Other ingredients with proven cardiovascular and cognitive benefits that will be promoted by Evonik during VitaFoods include Healthberry® 865, a natural anthocyanin-rich berry extract, and PentaQQTM, an innovative ingredient that stimulates mitochondrial biogenesis where studies indicate favorable cardio protective and neuroprotective effects.

May 15, 2018

Contact person Dr. Jürgen Krauter

Head of Communications Nutrition & Care Phone +49 6181 59-6847 Fax +49 6181 59-76847 juergen.krauter@evonik.com

Contact person specialized press Stephen Allan

External Communication Health Care Phone + 49 6151 18-3508 Fax +49 6151 1884-4019 stephen.allan@evonik.com

Evonik Nutrition & Care GmbH

Rellinghauser Straße 1-11 45128 Essen Telefone +49 201 177-01 Fax +49 201 177-3475 Germany

www.evonik.com

Supervisory Board

Dr. Harald Schwager, Chairman

Managing Directors

Dr. Reiner Beste, Chairman Dr. Hans Josef Ritzert Michael Gattermann Markus Schäfer

Registered office Essen Registered court Essen local court Commercial registry B 25784 HR no. FN 431387 v

Press release



Company information

Evonik is one of the world leaders in specialty chemicals. The focus on more specialty businesses, customer-orientated innovative prowess and a trustful and performance-oriented corporate culture form the heart of Evonik's corporate strategy. They are the lever for profitable growth and a sustained increase in the value of the company. Evonik benefits specifically from its customer proximity and leading market positions. Evonik is active in over 100 countries around the world with more than 36,000 employees. In fiscal 2017, the enterprise generated sales of €14.4 billion and an operating profit (adjusted EBITDA) of €2.36 billion.

About Nutrition & Care

The Nutrition & Care segment is led by Evonik Nutrition & Care GmbH and contributes to fulfilling basic human needs. That includes applications for everyday consumer goods as well as animal nutrition and health care. This segment employed about 8,250 employees, and generated sales of around €4.5 billion in 2017.

Disclaimer

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.